Equity Briefing : Neptune Jumps; Anthera & Synta Pharmaceuticals Plunge
(Thomson Reuters ONE) -
Anthera Pharmaceuticals Inc(NASDAQ:ANTH) is the biggest percentage loser in
today's session as the company said that its study of a drug in development for
the treatment of lupus patients didn't meet a main goal, forcing the company to
reshuffle its plans for a follow-up trial. Shares of the company are now down
69.50% at $0.84 after hitting a new low of $0.81 earlier in the session.
Neptune Technologies & Bioressources-Ord(NASDAQ:NEPT) extended its uptrend for
the fourth straight session and soared 9.84% to $4.80 after hitting a new 52-
week high of $4.84 after a note from BioMedReports hinted that a long
anticipated stock dividend may be announced shortly.
Orexigen Therapeutics, Inc.(NASDAQ:OREX) continued to move higher after
yesterday's up move of 20% as the FDA approved Arena Pharmaceuticals (ARNA)
Belviq weight loss drug. Analyst at JPMorgan upped its investment rating on the
stock to Overweight, citing the company "stands to be the biggest beneficiary"
as approval for its own weight loss drug, Contrave, is still far off, which
leaves a valuation gap with rivals whose drugs are closer to approval. Shares of
the company are now up 19.31% to $5.87 and made a new 52-week high of $5.88.
Synta Pharmaceuticals Corp.(NASDAQ:SNTA) shares are hammered down by 31.72% to
$4.95 after reporting mixed interim results from a Phase IIb/III trial of its
ganetespib treatment for lung cancer. Synta is assessing the drug in combination
with docetaxel, a leading chemotherapy.
Synergetics USA Inc.(NASDAQ:SURG) is among the top winners as the company won
FDA clearance for VersaVIT, a vitrectomy system for the retinal surgery market.
The stock is now up 27.13% at $4.92, although came off session high of $5.75.
Vertex Pharmaceuticals Incorporated(NASDAQ:VRTX) lost about 13% despite the
company said a mid-stage study showing a combination of its VX-80 and Kalydeco
drugs for cystic fibrosis helped improve lung function in patients. "The highest
dose arm looks good," says ISI analyst Mark Schoenebaum, who reiterates his
"buy" rating on the stock.
This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: Equity Briefing via Thomson Reuters ONE
[HUG#1622855]
Themen in dieser Pressemitteilung:
Unternehmensinformation / Kurzprofil:
Datum: 28.06.2012 - 14:10 Uhr
Sprache: Deutsch
News-ID 1129074
Anzahl Zeichen: 0
contact information:
Contact person:
Town:
Phone:
Kategorie:
Business News
Anmerkungen:
Diese Pressemitteilung wurde bisher 67 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Equity Briefing : Neptune Jumps; Anthera & Synta Pharmaceuticals Plunge
"
steht unter der journalistisch-redaktionellen Verantwortung von
Equity Briefing (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
